Toll Free: 1-888-928-9744

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals

Published: May 1, 2016 | Pages: 97 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons To Buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
 Table of Contents
1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 9 2 Pharmaceuticals & Healthcare, Global, Deal Summary 12 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2016 12 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2016 14 2.2.1 Sanofi Prices Public Offering of Notes For USD2 Billion 14 2.2.2 Perrigo Raises USD1.2 Billion in Public Offering of Notes 14 2.2.3 Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 15 2.2.4 AmerisourceBergen Raises USD1.17 Billion in Private Placement of Shares up on Exercise of Warrants 15 2.2.5 Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 15 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2016 17 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2016 18 3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19 3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2016 19 3.1.1 Top M&A Deals in March 2016 20 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2015 - March 2016 21 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2016 22 3.2.1 Top Equity Offering Deals in March 2016 23 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2015 - March 2016 24 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2016 25 3.3.1 Top PE/VC Deals in March 2016 26 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2016 27 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2016 28 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, October 2015-March 2016 30 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2015-March 2016 31 4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2016 32 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2016 32 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2015 - March 2016 34 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2016 35 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2016 36 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 37 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2015 - March 2016 39 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2015 - March 2016 40 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 42 5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2016 44 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2016 44 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2016 46 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2015 - March 2016 48 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2015 - March 2016 49 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2015 - March 2016 51 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2015 - March 2016 53 5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2016 54 5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2016 55 5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2016 55 6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 56 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2016 56 6.1.1 Oncology - Deals of the Month 57 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2016 60 6.2.1 Central Nervous System - Deals of the Month 61 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2016 63 6.3.1 Infectious Diseases - Deals of the Month 64 6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2016 66 6.4.1 Cardiovascular - Deals of the Month 67 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2016 69 6.5.1 Immunology - Deals of the Month 70 6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, March 2016 72 6.6.1 Gastrointestinal - Deal of the Month 73 6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2016 75 6.7.1 Metabolic Disorders - Deal of the Month 76 7 Deal Summary by Geography 78 7.1 Pharmaceuticals & Healthcare, North America Deals, March 2016 78 7.1.1 North America - Deals of the Month 79 7.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2016 82 7.2.1 Europe - Deals of the Month 83 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2016 85 7.3.1 Asia-Pacific - Deals of the Month 86 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2016 88 7.4.1 Rest of the World - Deals of the Month 89 8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 90 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2015 - March 2016 90 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2015 - March 2016 92 9 Further Information 94 9.1 Methodology 94 9.2 About GlobalData 95 9.3 Disclosure information 95 9.4 Disclaimer 96
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 13 Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2016 14 Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2016 18 Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 20 Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2016 20 Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2015 - March 2016 21 Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 23 Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2016 23 Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 24 Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 26 Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2016 26 Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2015 - March 2016 27 Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2016 29 Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 30 Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2015 - March 2016 31 Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 33 Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 34 Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 35 Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2016 36 Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 38 Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 41 Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2015 - March 2016 43 Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 45 Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 47 Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 48 Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2016 50 Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 52 Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2016 54 Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2016 54 Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2016 55 Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2016 55 Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 57 Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 61 Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 64 Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 67 Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 70 Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 73 Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 76 Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 79 Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 83 Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 86 Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 89 Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 91 Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 93


List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 12 Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2016 17 Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2016 18 Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 19 Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2015 - March 2016 21 Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 22 Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 24 Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 25 Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2015 - March 2016 27 Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2016 28 Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2016 29 Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 30 Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 32 Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 34 Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 35 Figure 16:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 37 Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 39 Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 40 Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 42 Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 44 Figure 21:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 46 Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 48 Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 49 Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2015 - March 2016 51 Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2015 - March 2016 52 Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2016 53 Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 56 Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 60 Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 63 Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 66 Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 69 Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 72 Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 75 Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 78 Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 82 Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 85 Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 88 Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 90 Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 92

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...
Choose License Type
Single User - US $1000
Multi User - US $2000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify